TIFFANY FRANKS: Open Payments
NPI 1780263640 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 42 payments from 13 companies in 2025. Trend: 2023 $42 · 2024 $264 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $276 |
| AstraZeneca Pharmaceuticals LP | 9 | $251 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $168 |
| GENZYME CORPORATION | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $44 |
| Amgen Inc. | 2 | $37 |
| Novartis Pharmaceuticals Corporation | 2 | $35 |
| Genentech USA, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $16 |
Products named: DUPIXENT, TEZSPIRE, NEFFY, FASENRA, CUVITRU, Xembify, Xolair, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
